Idenix Pharmaceuticals LLC v Gilead Sciences Pty Ltd [2017] FCAFC 196

Idenix Pharmaceuticals LLC v Gilead Sciences Pty Ltd [2017] FCAFC 196

The Idenix patent, when considered alongside common general knowledge, did not enable skilled addressees to produce compounds within claim 7 without new inventions or prolonged study of matters presenting initial difficulty. The specification and incorporated priority documents provided broad disclosures but lacked real and reasonably clear disclosure for certain claimed compounds, and there was insufficient guidance for direct synthesis. Consequently, the relevant claims were invalid for insufficiency. Although priority was properly based on the 949 application, allowing the patent to escape anticipation by the Clark patent, the appeal was dismissed and the primary judge's findings...

Parties
First Appellant: Idenix Pharmaceuticals LLC; Second Appellant: Universita degli Studi di Cagliari; Third Appellant: Centre National de la Recherche Scientifique; Fourth Appellant: Universite de Montpellier; Fifth Appellant: Idenix (Cayman) Limited; First Respondent: Gilead Sciences Pty Ltd; Second Respondent: Gilead Sciences Inc
Jurisdiction
Australia
Judgment Date
07 December 2017
Procedural Posture
Appeal / Final Judgment
Outcome
Appeal dismissed
Legal Topics
Patents, Pharmaceutical Patents, Sufficiency, Fair Basis, Utility, Novelty
Intellectual Property Patents Pharmaceutical Patents Sufficiency Fair Basis Utility Novelty

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 4 Authorities cited 23 Party arguments 2
Sign in to unlock

Parties

Idenix Pharmaceuticals LLC

First Appellant

Universita degli Studi di Cagliari

Second Appellant

Centre National de la Recherche Scientifique

Third Appellant

Universite de Montpellier

Fourth Appellant

Idenix (Cayman) Limited

Fifth Appellant

Gilead Sciences Pty Ltd

First Respondent

Gilead Sciences Inc

Second Respondent

Procedural Posture

Appeal / Final Judgment

Legal Issues

  1. 1 Whether the Idenix patent sufficiently describes the invention and enables the skilled addressee to produce the claimed compounds without new inventions or prolonged study
  2. 2 Whether claims are fairly based on matter disclosed in earlier applications and entitled to those priority dates
  3. 3 Whether the patent claims lack utility and novelty

Ratio Decidendi

The Idenix patent, when considered alongside common general knowledge, did not enable skilled addressees to produce compounds within claim 7 without new inventions or prolonged study of matters presenting initial difficulty. The specification and incorporated priority documents provided broad disclosures but lacked real and reasonably clear disclosure for certain claimed compounds, and there was insufficient guidance for direct synthesis. Consequently, the relevant claims were invalid for insufficiency. Although priority was properly based on the 949 application, allowing the patent to escape anticipation by the Clark patent, the appeal was dismissed and the primary judge's findings...

Court Disposition

Appeal dismissed

Orders

  • The appeal be dismissed.
  • Within 14 days, parties file and serve written submissions (limited to 3 pages) on the question of costs.